Envestnet Asset Management Inc. Raises Holdings in Agilent Technologies, Inc. $A

Envestnet Asset Management Inc. grew its stake in Agilent Technologies, Inc. (NYSE:A) by 3.8% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 607,914 shares of the medical research company’s stock after buying an additional 22,498 shares during the quarter. Envestnet Asset Management Inc. owned 0.21% of Agilent Technologies worth $78,026,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Capital A Wealth Management LLC raised its holdings in Agilent Technologies by 10,600.0% in the second quarter. Capital A Wealth Management LLC now owns 214 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 212 shares in the last quarter. Davis Capital Management acquired a new stake in shares of Agilent Technologies in the 3rd quarter valued at $28,000. Physician Wealth Advisors Inc. raised its holdings in shares of Agilent Technologies by 490.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 236 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 196 shares in the last quarter. State of Wyoming purchased a new stake in shares of Agilent Technologies during the 2nd quarter worth $35,000. Finally, SJS Investment Consulting Inc. grew its stake in shares of Agilent Technologies by 2,836.4% during the third quarter. SJS Investment Consulting Inc. now owns 323 shares of the medical research company’s stock worth $41,000 after purchasing an additional 312 shares in the last quarter. 87.41% of the stock is owned by institutional investors and hedge funds.

Agilent Technologies Trading Up 0.1%

A opened at $129.76 on Monday. The company has a quick ratio of 1.52, a current ratio of 1.96 and a debt-to-equity ratio of 0.45. Agilent Technologies, Inc. has a 52 week low of $96.43 and a 52 week high of $160.27. The business’s 50 day moving average is $139.96 and its two-hundred day moving average is $135.26. The firm has a market cap of $36.79 billion, a price-to-earnings ratio of 28.39, a price-to-earnings-growth ratio of 3.76 and a beta of 1.30.

Agilent Technologies (NYSE:A) last announced its earnings results on Monday, November 24th. The medical research company reported $1.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.01. The business had revenue of $1.86 billion for the quarter, compared to analyst estimates of $1.83 billion. Agilent Technologies had a net margin of 18.75% and a return on equity of 25.20%. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period last year, the firm posted $1.46 earnings per share. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS and its FY 2026 guidance at 5.860-6.000 EPS. On average, research analysts predict that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, January 28th. Shareholders of record on Tuesday, January 6th were paid a $0.255 dividend. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.25. This represents a $1.02 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date was Tuesday, January 6th. Agilent Technologies’s dividend payout ratio (DPR) is presently 22.32%.

Insider Transactions at Agilent Technologies

In other news, VP Rodney Gonsalves sold 3,000 shares of the company’s stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $154.99, for a total value of $464,970.00. Following the completion of the sale, the vice president directly owned 31,846 shares of the company’s stock, valued at approximately $4,935,811.54. This represents a 8.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Padraig Mcdonnell sold 911 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $143.24, for a total value of $130,491.64. Following the transaction, the chief executive officer directly owned 32,058 shares in the company, valued at approximately $4,591,987.92. This represents a 2.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 16,401 shares of company stock valued at $2,468,962 over the last ninety days. Corporate insiders own 0.26% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on A shares. The Goldman Sachs Group initiated coverage on Agilent Technologies in a research note on Tuesday, December 9th. They issued a “buy” rating and a $170.00 price target on the stock. Wells Fargo & Company raised their target price on Agilent Technologies from $150.00 to $175.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 25th. HSBC assumed coverage on Agilent Technologies in a research note on Tuesday, January 20th. They set a “buy” rating and a $180.00 target price for the company. Morgan Stanley began coverage on shares of Agilent Technologies in a report on Tuesday, December 2nd. They set an “overweight” rating on the stock. Finally, UBS Group upped their target price on shares of Agilent Technologies from $170.00 to $180.00 and gave the company a “buy” rating in a report on Tuesday, November 25th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, Agilent Technologies presently has an average rating of “Moderate Buy” and a consensus target price of $164.50.

Agilent Technologies Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.